PL2598160T3 - Stabilizacja fsh - Google Patents

Stabilizacja fsh

Info

Publication number
PL2598160T3
PL2598160T3 PL11736111T PL11736111T PL2598160T3 PL 2598160 T3 PL2598160 T3 PL 2598160T3 PL 11736111 T PL11736111 T PL 11736111T PL 11736111 T PL11736111 T PL 11736111T PL 2598160 T3 PL2598160 T3 PL 2598160T3
Authority
PL
Poland
Prior art keywords
fsh
stabilization
Prior art date
Application number
PL11736111T
Other languages
English (en)
Inventor
Helen Ulrika Sjögren
Heidi Louise Bagger
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43216624&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2598160(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of PL2598160T3 publication Critical patent/PL2598160T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
PL11736111T 2010-07-30 2011-07-28 Stabilizacja fsh PL2598160T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
EP11736111.3A EP2598160B1 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Publications (1)

Publication Number Publication Date
PL2598160T3 true PL2598160T3 (pl) 2017-06-30

Family

ID=43216624

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11736111T PL2598160T3 (pl) 2010-07-30 2011-07-28 Stabilizacja fsh

Country Status (27)

Country Link
US (3) US8993732B2 (pl)
EP (3) EP2417982A1 (pl)
JP (3) JP5860047B2 (pl)
KR (2) KR101991756B1 (pl)
CN (2) CN105106939A (pl)
AR (1) AR082776A1 (pl)
AU (1) AU2011284702C1 (pl)
BR (1) BR112013002312B1 (pl)
CA (1) CA2805864A1 (pl)
DK (1) DK2598160T3 (pl)
ES (1) ES2623634T3 (pl)
HR (1) HRP20170386T1 (pl)
HU (1) HUE033592T2 (pl)
IL (2) IL223821A (pl)
JO (1) JO3229B1 (pl)
LT (1) LT2598160T (pl)
MX (2) MX341464B (pl)
NZ (2) NZ606366A (pl)
PL (1) PL2598160T3 (pl)
PT (1) PT2598160T (pl)
RS (1) RS55772B1 (pl)
RU (1) RU2574012C2 (pl)
SA (1) SA114350786B1 (pl)
SI (1) SI2598160T1 (pl)
TW (1) TWI439283B (pl)
WO (1) WO2012013742A2 (pl)
ZA (1) ZA201209497B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
KR101699677B1 (ko) * 2013-11-12 2017-01-24 카딜라 핼쓰캐어 리미티드 고나도트로핀을 위한 제제
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种***的长效制剂
GB201603280D0 (en) * 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3723728A1 (fr) 2017-12-07 2020-10-21 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
BR112020011570A2 (pt) 2017-12-07 2020-12-08 Adocia Solução injetável a um ph 7 compreendendo pelo menos uma insulina basal apresentando um pi entre 5,8 e 8,5 e um co-poliaminoácido contendo cargas de carboxilato e radicais hidrofóbicos
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたhmgb1含有溶液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU607001A1 (ru) * 1976-01-14 1978-05-15 Краснодарский Государственный Научно-Исследовательский И Проектный Институт Нефтяной Промышленности Способ получени кислотного раствора
ES2166841T3 (es) 1995-03-21 2002-05-01 Applied Research Systems Formulaciones liquidas de hcg.
CA2257172C (en) * 1996-05-29 2005-04-12 Orion Corporation Dissolvable oxides for biological applications
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
BRPI0508798A (pt) * 2004-04-07 2007-09-04 Ares Trading Sa formulação lìquida de hormÈnio de crescimento, composição farmacêutica, forma de apresentação da formulação lìquida de hormÈnio de crescimento e uso da formulação lìquida de hormÈnio de crescimento
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
EP3366692A1 (en) * 2009-06-22 2018-08-29 Amgen, Inc Refolding proteins using a chemically controlled redox state
CN102821782B (zh) * 2010-02-12 2015-07-15 印塔斯生物制药有限公司 促卵泡激素的液体配制品
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Also Published As

Publication number Publication date
EP2598160A2 (en) 2013-06-05
JP2016102127A (ja) 2016-06-02
CN103052398A (zh) 2013-04-17
NZ628962A (en) 2016-01-29
IL249920A0 (en) 2017-03-30
SA114350786B1 (ar) 2015-07-09
AU2011284702C1 (en) 2015-09-03
JP6522711B2 (ja) 2019-05-29
MX341464B (es) 2016-08-22
JP2018048188A (ja) 2018-03-29
TWI439283B (zh) 2014-06-01
US20170216405A1 (en) 2017-08-03
JP2013532677A (ja) 2013-08-19
PT2598160T (pt) 2017-03-30
RU2012157154A (ru) 2014-09-10
MX356951B (es) 2018-06-21
ZA201209497B (en) 2013-08-28
US9463221B2 (en) 2016-10-11
LT2598160T (lt) 2017-04-10
AU2011284702A1 (en) 2013-02-07
KR20130143692A (ko) 2013-12-31
AU2011284702B2 (en) 2015-05-14
TW201208694A (en) 2012-03-01
CN105106939A (zh) 2015-12-02
KR101820115B1 (ko) 2018-01-18
US8993732B2 (en) 2015-03-31
JP5860047B2 (ja) 2016-02-16
RU2574012C2 (ru) 2016-01-27
CA2805864A1 (en) 2012-02-02
CN103052398B (zh) 2015-09-16
AR082776A1 (es) 2013-01-09
HUE033592T2 (hu) 2017-12-28
WO2012013742A3 (en) 2012-04-19
KR101991756B1 (ko) 2019-06-21
HRP20170386T1 (hr) 2017-05-05
JO3229B1 (ar) 2018-03-08
US20150265681A1 (en) 2015-09-24
IL223821A (en) 2017-01-31
NZ606366A (en) 2014-08-29
RS55772B1 (sr) 2017-07-31
SI2598160T1 (sl) 2017-07-31
EP2598160B1 (en) 2017-02-22
MX2013000681A (es) 2013-02-27
EP2417982A1 (en) 2012-02-15
BR112013002312B1 (pt) 2021-09-21
KR20180008916A (ko) 2018-01-24
US20130210727A1 (en) 2013-08-15
ES2623634T3 (es) 2017-07-11
WO2012013742A2 (en) 2012-02-02
DK2598160T3 (en) 2017-03-27
BR112013002312A2 (pt) 2018-03-20
EP3144010A1 (en) 2017-03-22

Similar Documents

Publication Publication Date Title
IL249920A0 (en) Stabilization of follicle stimulating hormone
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
GB2500337B (en) Vector conflict instructions
EP2813073A4 (en) ADAPTIVE TARGET
HK1171476A1 (en) Apparatuses
EP2579794A4 (en) RECIPIENT FOR CONFORMING BONE STABILIZATION
IL243810A0 (en) vehicle stabilization
EP2639303A4 (en) NEW EXPRESSION VECTOR
AU335554S (en) Television
EP2538819A4 (en) STABILIZATION OF OBJECTS
SI2407155T1 (sl) Preparati na osnovi inekalcitola
EP2839332A4 (en) OPTIMIZED IMAGE STABILIZATION
EP2536693A4 (en) SUBSTITUTED 2-IMIDAZOLIDONES AND THE LIKE
IL212002A0 (en) Stabilization of captured images
GB201015229D0 (en) Vehicle stabilization
TWM386036U (en) Structure of freshness-maintaining box
TWM400763U (en) Improved structure of cold-accumulating cravats
TWM388315U (en) Improved structure of hemoclip
GB201009052D0 (en) Vector
TWM390349U (en) Structure of door-in-door
TWM386865U (en) Residue-filtering structure of juice-extractor
TWM401669U (en) Improved structure of socket
HU1000688D0 (en) Use of trifluoro-phal
AU334485S (en) Television
AU334474S (en) Television